UK supply of Pfizer vaccine tight but on track for targets -minister



LONDON, June 11 (Reuters) - Britain's vaccine minister said on Friday that supplies of the Pfizer-BioNTech PFE.N vaccine for coronavirus would be "tight" over the next few weeks but that he was confident that the country's immunisation targets would be met.

"It is tight," vaccine minister Nadhim Zahawi said on Pfizer supplies when asked on LBC radio.

"I'm confident that Scotland will be able to meet the target of offering every adult at least one dose by the end of July as we will in England as well," he added.

Britain said on Thursday that it would give at least 100 million surplus vaccines to the world's poorest nations. Zahawi said the donations would not affect the domestic vaccine programme.

"No doses that are required for Scotland, for Northern Ireland, for Wales, for England are being taken away by our announcement (on donating vaccines)," Zahawi said.
Reporting by Sarah Young and Paul Sandle; editing by Michael Holden

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

We are using cookies to give you the best experience on our website. Read more or change your cookie settings.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.